| Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC) |
Recruiting |
Locally Advanced/ Metastatic NSCLC |
NCT04208854 |
| Vinorelbine in Advanced BRAF-like Colon Cancer |
Recruiting |
Colon Cancer |
NCT03482362 |
| Vinorelbine for Recurrent ALCL-2017 |
Recruiting |
Anaplastic Large Cell Lymphoma|Vinorelbine |
NCT03443128 |
| Vinorelbine for Recurrent ACLC |
Recruiting |
Anaplastic Large Cell Lymphoma|Vinorelbine |
NCT03397953 |
| Vinorelbine in Mesothelioma |
Active, not recruiting |
Mesothelioma |
NCT02139904 |
| Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT03007992 |
| A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma |
Recruiting |
Lung Adenocarcinoma |
NCT03891173 |
| Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer |
Not yet recruiting |
Triple-negative Breast Cancer |
NCT03932526 |
| Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer |
Completed |
Advanced Non Small Cell Lung Cancer |
NCT03652857 |
| Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas |
Completed |
Low-grade Glioma |
NCT01497860 |
| Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca |
Unknown status |
Breast Cancer |
NCT02144194 |
| Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma |
Active, not recruiting |
Low-Grade Glioma |
NCT02197637 |
| Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer |
Terminated |
Breast Cancer|Metastatic Breast Cancer |
NCT02658084 |
| Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA) |
Completed |
Breast Cancer |
NCT02802748 |
| A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer |
Recruiting |
Breast Cancer|Brain Metastases |
NCT03933982 |
| Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma |
Not yet recruiting |
Rhabdomyosarcoma |
NCT04299113 |
| Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer |
Terminated |
Lung Neoplasm Malignant |
NCT02985203 |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer |
Recruiting |
Ovarian Cancer|Fallopian Tube Cancer |
NCT03188159 |
| Vinorelbine and Gemcitabine in Myeloma |
Completed |
Multiple Myeloma|Amyloidosis |
NCT02791373 |
| Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00912275 |
| Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT02768415 |
| Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. |
Not yet recruiting |
HER2 Positive Breast Cancer |
NCT03947242 |
| Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer |
Terminated |
Breast Cancer |
NCT00176488 |
| Satraplatin and Vinorelbine in Advanced Solid Tumors |
Unknown status |
Advanced Solid Tumors |
NCT01220284 |
| Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. |
Recruiting |
Metastatic Breast Cancer |
NCT04265274 |
| Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab |
Unknown status |
Metastatic Breast Cancer |
NCT01730677 |
| Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00870532 |
| Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00702182 |
| Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00706069 |
| Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer |
Terminated |
Malignant Solid Tumour |
NCT00801151 |
| GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial |
Unknown status |
Non Small Cell Lung Cancer |
NCT02319577 |
| Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria |
Completed |
Non-Small-Cell Lung Cancer|Breast Cancer |
NCT02619929 |
| Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer |
Not yet recruiting |
Metastatic Breast Cancer |
NCT04143906 |
| Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer |
NCT01196559 |
| Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy |
Not yet recruiting |
Pathologic Residual Cancer Cells |
NCT03703427 |
| Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer |
Recruiting |
Non-small Cell Lung Cancer |
NCT03801304 |
| A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer |
Recruiting |
Hormone Receptor Positive Advanced Breast Cancer |
NCT03939871 |
| Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer |
Recruiting |
Advanced Triple-Negative Breast Cancer |
NCT03254654 |
| A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases |
Completed |
HER-2 Positive Breast Cancer |
NCT01305941 |
| Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer |
Terminated |
Metastatic Non Small Cell Lung Cancer|Metastatic Breast Cancer |
NCT01060514 |
| Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC |
Completed |
Non-small Cell Lung Cancer Metastatic |
NCT01848613 |
| BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours |
Completed |
Neoplasms |
NCT01214616 |
| Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00755170 |
| Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma |
Completed |
Metastatic Melanoma |
NCT00256282 |
| A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy |
Recruiting |
Breast Cancer |
NCT04302441 |
| Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00754702 |
| Trastuzumab and Vinorelbine in Advanced Breast Cancer |
Terminated |
Breast Cancer|Metastatic Breast Cancer |
NCT01185509 |
| Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy |
Completed |
Lung Cancer |
NCT01839032 |
| Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00513058 |
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer |
Terminated |
Metastatic Breast Cancer|HER2 Positive|First or Second Line Therapy|Failure or Contraindication of Trastuzumab Therapy |
NCT01238029 |
| Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects |
Terminated |
Neoplasms, Breast |
NCT00709618 |
| Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT00764972 |
| Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors |
Completed |
Advanced Malignant Solid Tumors |
NCT00958724 |
| Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma |
Completed |
Esophageal Cancer|Gastric Cancer|Stomach Cancer |
NCT00215462 |
| Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer |
Completed |
Prostate Cancer |
NCT00151086 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors |
Completed |
Extensive Stage Small Cell Lung Cancer|Hereditary Paraganglioma|Male Breast Cancer|Malignant Paraganglioma|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Pheochromocytoma|Pancreatic Polypeptide Tumor|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Endometrial Carcinoma|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Neuroendocrine Carcinoma of the Skin|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pheochromocytoma|Recurrent Prostate Cancer|Recurrent Renal Cell Cancer|Recurrent Small Cell Lung Cancer|Recurrent Uterine Sarcoma|Regional Gastrointestinal Carcinoid Tumor|Regional Pheochromocytoma|Stage III Cervical Cancer|Stage III Endometrial Carcinoma|Stage III Neuroendocrine Carcinoma of the Skin|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage III Prostate Cancer|Stage III Renal Cell Cancer|Stage III Uterine Sarcoma|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Endometrial Carcinoma|Stage IV Neuroendocrine Carcinoma of the Skin|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Prostate Cancer|Stage IV Renal Cell Cancer|Stage IV Uterine Sarcoma|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Thyroid Gland Medullary Carcinoma |
NCT01155258 |
| Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients |
Recruiting |
Advanced Breast Cancer |
NCT04304352 |
| A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients |
Terminated |
Metastatic Breast Cancer |
NCT01161368 |
| S9804: Vinorelbine in Treating Patients With Stage IV Melanoma |
Completed |
Melanoma (Skin) |
NCT00003828 |
| Lapatinib in Combination With Vinorelbine |
Completed |
Cancer |
NCT01128543 |
| Locally Advanced Trial of Tri-weekly Metronomic Oral Vinorelbine and Cisplatin as Induction Therapy and Subsequent Concomitance With Radiation Therapy in Patients With Unresectable Non Small Cell Lung Cancer (NSCLC) |
Completed |
Lung Cancer |
NCT02709720 |
| Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01941771 |
| Metronomic Oral Vinorelbine in Patients With Metastatic Tumors |
Completed |
Breast Cancer|Non Small Cell Lung Cancer|Prostate Cancer |
NCT00278070 |
| Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM |
Unknown status |
Non Small Cell Lung Cancer (NSCLC)|Malignant Pleural Mesothelioma (MPM) |
NCT02555007 |
| Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00675597 |
| Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer |
Terminated |
Breast Cancer |
NCT00694200 |
| Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial |
Unknown status |
Breast Cancer |
NCT01528826 |
| Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC) |
Unknown status |
Non-small Cell Lung Cancer |
NCT01258127 |
| Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy |
Recruiting |
Cancer |
NCT02925000 |
| Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients |
Unknown status |
Non-small Cell Lung Cancer|Effects of Chemotherapy |
NCT01749072 |
| Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00828074 |
| Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations |
Completed |
Breast Cancer |
NCT02628613 |
| Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) |
Recruiting |
Breast Cancer |
NCT04296162 |
| A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer |
Not yet recruiting |
Metastatic Breast Cancer |
NCT03997539 |
| Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients |
Completed |
Breast Cancer|Neoplasm Metastasis |
NCT00128310 |
| Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00545948 |
| Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00532623 |
| Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial |
Completed |
Non-small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV |
NCT02176369 |
| PemVin vs Vin in Previously Treated Metastatic Breast Cancer |
Unknown status |
Breast Neoplasms |
NCT03242616 |
| Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00165334 |
| Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer |
Completed |
Breast Cancer|Advanced Malignant Solid Tumors |
NCT00706030 |
| Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer |
Completed |
Her2-negative Metastatic Breast Cancer|Her2-negative Locally Advanced Breast Cancer |
NCT01520103 |
| Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00670982 |
| A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease |
Active, not recruiting |
Breast Cancer |
NCT02730091 |
| BIBW 2992 (Afatinib) and Vinorelbine |
Terminated |
Carcinoma Breast Stage IV |
NCT01531764 |
| Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT01405079 |
| Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours |
Recruiting |
Advanced Solid Tumours|Breast Cancer|Head and Neck Cancer|Cervix Cancer|Prostate Cancer |
NCT03518606 |
| Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse |
Unknown status |
Rhabdomyosarcomas|Neoplasms, Connective and Soft Tissue|Ewing Tumor|Osteosarcomas|Neuroblastomas|Medulloblastomas |
NCT00180947 |
| Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes |
Completed |
HER2-Negative Breast Cancer|Triple Negative Breast Cancer|Breast Cancer|Cancer of Breast|Breast Tumors |
NCT02225470 |
| Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC) |
Completed |
Breast Cancer|Metastasis, Neoplasm |
NCT00629148 |
| Lapatinib in Combination With Vinorelbine |
Completed |
Cancer |
NCT01013740 |
| Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients |
Unknown status |
Hodgkin's Lymphoma |
NCT01884441 |
| Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer |
Completed |
Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer |
NCT00017394 |
| Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer |
Unknown status |
Small Cell Lung Cancer |
NCT01752517 |
| Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation |
Completed |
Lymphoma |
NCT00003963 |
| Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) |
Completed |
Non Small Cell Lung Cancer |
NCT00441922 |
| Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00008333 |
| Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm |
Completed |
Advanced Neoplasm |
NCT00908869 |
| Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer |
Completed |
Advanced Non-Small Cell Lung Cancer |
NCT00737867 |
| Vinorelbine in Treating Older Women With Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00022152 |
| Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer |
Completed |
HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer |
NCT01007942 |
| Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01439191 |
| Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00431106 |
| Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2 |
Completed |
Neoplasms |
NCT00906698 |
| Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC. |
Completed |
Lung Neoplasm |
NCT00295672 |
| A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer |
Withdrawn |
Advanced Breast Cancer|HER2-positive Breast Cancer |
NCT03811418 |
| Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. |
Terminated |
Breast Cancer |
NCT02585388 |
| Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas |
Completed |
Sarcoma, Soft Tissue |
NCT00134641 |
| A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer |
Completed |
Breast Cancer |
NCT01565083 |
| An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT01684111 |
| Phase II Iressa Versus Vinorelbine (INVITE) |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00256711 |
| A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer. |
Completed |
Breast Cancer|Non-small Cell Lung Cancer|Non-Hodgkins Lymphoma |
NCT00432562 |
| Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer |
Completed |
Lung Neoplasms|Carcinoma|Cancer of the Lung|Non-Small-Cell Lung Carcinoma |
NCT01109524 |
| Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer |
NCT00602797 |
| Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00372476 |
| Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer |
Completed |
Advanced Non-small Cell Lung Cancer |
NCT03117335 |
| A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00192062 |
| Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies |
Unknown status |
Nonhematologic Malignancies |
NCT00641160 |
| Vinorelbine in Treating Children With Recurrent or Refractory Cancers |
Completed |
Brain and Central Nervous System Tumors|Neuroblastoma|Sarcoma |
NCT00003234 |
| Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer |
Terminated |
Breast Cancer |
NCT01254136 |
| Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases |
Completed |
Metastatic Cancer |
NCT00026494 |
| A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer |
Terminated |
Stage IV (Metastatic) Breast Cancer |
NCT00140140 |
| Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients |
Terminated |
Breast Cancer |
NCT00453635 |
| Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC |
Completed |
Non Small Cell Lung Cancer |
NCT00496275 |
| Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer |
Completed |
Lung Cancer |
NCT00287963 |
| Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT01242449 |
| NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy |
Recruiting |
Breast Cancer |
NCT04307147 |
| Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00075673 |
| Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
Unknown status |
Non-Small Cell Lung Cancer |
NCT00678964 |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer |
Recruiting |
Breast Cancer |
NCT03414658 |
| Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer |
Completed |
Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Hereditary Breast/Ovarian Cancer - BRCA1|Hereditary Breast/Ovarian Cancer - BRCA2|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer |
NCT01104259 |
| Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00093808 |
| Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer |
Completed |
Breast Cancer |
NCT00193089 |
| Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT02544243 |
| Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer|Stage IV Breast Cancer |
NCT00146549 |
| Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma |
Completed |
Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Pleomorphic Rhabdomyosarcoma|Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Childhood Rhabdomyosarcoma |
NCT01222715 |
| Navelbine And Radiotherapy in Locally Advanced Lung Cancer |
Unknown status |
Non-small Cell Lung Cancer |
NCT00887783 |
| An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT01683682 |
| Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) |
Completed |
Non Small Cell Lung Cancer (NSCLC) |
NCT00148798 |
| Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer |
Completed |
Breast Neoplasm |
NCT00194727 |
| VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT00431704 |
| Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00266110 |
| Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00389922 |
| Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00325234 |
| Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy |
Withdrawn |
Prostate Cancer |
NCT00003622 |
| Clinical Observation of S1 Capsule for Stage â…ˇ-â…˘A Non-small Cell Lung Cancer After Complete Resection |
Unknown status |
Non-small Cell Lung Cancer Stage â…ˇ|Non-small Cell Lung Cancer Stage â…˘A |
NCT02223611 |
| Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma |
Completed |
Lymphoma |
NCT00070304 |
| Vinorelbine in Treating Patients With Metastatic Prostate Cancer |
Completed |
Prostate Cancer |
NCT00003259 |
| Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors |
Unknown status |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00006088 |
| Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis |
Completed |
Bladder Cancer|Cervical Cancer|Endometrial Cancer|Vaginal Cancer |
NCT00002949 |
| Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00088985 |
| Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00441740 |
| A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT00159094 |
| Vinorelbine Plus Cisplatin or No Further Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed |
Completed |
Lung Cancer |
NCT00002583 |
| S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00041067 |
| Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy NaĂŻve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression |
Terminated |
Carcinoma, Non-Small-Cell Lung|Secondary|Advanced Stage IIIB|High Thymidylate Synthase Expression |
NCT02919462 |
| Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment |
Withdrawn |
Lymphoma |
NCT00881387 |
| Lux-Breast 3 |
N/A |
N/A |
NCT01441596 |
| the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment |
Terminated |
Triple Negative Breast Cancer |
NCT03358004 |
| Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations |
Unknown status |
Non-small Cell Lung Cancer Stage IIIA |
NCT01410214 |
| GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL |
Recruiting |
Lymphoma, Large B-Cell, Diffuse |
NCT04021992 |
| Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00309998 |
| Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer |
Recruiting |
Esophageal Squamous Cell Carcinoma|Esophageal Cancer|Oesophageal Cancer |
NCT02465736 |
| Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy |
Completed |
Non Small Cell Lung Cancer |
NCT00349089 |
| Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00148291 |
| Vinorelbine and XR9576 to Treat Cancer |
Completed |
Breast Cancer|Cancer|Lung Cancer|Ovarian Cancer |
NCT00001944 |
| Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) |
Completed |
Mesothelioma |
NCT02610140 |
| Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00005865 |
| Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction |
Completed |
Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00540982 |
| Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00103233 |
| An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma |
Terminated |
Mesothelioma |
NCT00597116 |
| Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients |
Completed |
Non Small Cell Lung Cancer |
NCT00271271 |
| Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma |
Terminated |
Breast Neoplasms |
NCT00403988 |
| HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00401427 |
| Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00153907 |
| Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy |
Completed |
Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Lymphocyte Predominant Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma |
NCT00381940 |
| Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial |
Terminated |
Breast Cancer |
NCT00041470 |
| Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function |
Terminated |
Metastatic Breast Cancer |
NCT00169104 |
| LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment |
Completed |
Breast Neoplasms |
NCT01125566 |
| Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00003447 |
| S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00015938 |
| Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients |
Not yet recruiting |
2-year Disease-Free Survival |
NCT03203590 |
| Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer |
Completed |
Breast Cancer |
NCT00148668 |
| Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer |
Completed |
NSCLC |
NCT00683514 |
| Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00049660 |
| Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00006682 |
| Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer |
Unknown status |
Non-small Cell Lung Cancer |
NCT00576914 |
| Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer |
Completed |
Breast|Cancer |
NCT00277069 |
| Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00868634 |
| Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00003730 |
| Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT01124253 |
| A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer |
Not yet recruiting |
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
NCT03854617 |
| Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement |
Completed |
Breast Cancer |
NCT00003902 |
| Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00724386 |
| Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) |
Completed |
Breast Cancer |
NCT00503750 |
| Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma |
Recruiting |
Stage Ib Lung Carcinoma |
NCT02281708 |
| Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma |
Completed |
Non-Hodgkin's Lymphoma|Hodgkin's Disease |
NCT00163748 |
| S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00026156 |
| Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer |
Unknown status |
Breast Cancer |
NCT00430001 |
| Preoperative Herceptin and Navelbine for Breast Cancer |
Completed |
Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer |
NCT00148681 |
| Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer |
Completed |
Breast Cancer |
NCT00014430 |
| Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer |
Unknown status |
Anthracycline-pretreated Metastatic Breast Cancer |
NCT01635465 |
| PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma |
Completed |
Myeloma |
NCT01220375 |
| Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors |
Completed |
Wilms' Tumor|Sarcoma|Adenaocortical Carcinoma|Refractory Cancer|Coldrhood Cancer |
NCT00011414 |
| Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma |
Completed |
Lymphoma |
NCT00006760 |
| Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer |
Completed |
Breast Cancer |
NCT00544765 |
| Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT00480597 |
| Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma |
Completed |
Malignant Pleural Mesothelioma |
NCT00272558 |
| Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00017459 |
| Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00004096 |
| Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC |
Completed |
Non Small Cell Lung Cancer |
NCT00620971 |
| A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer. |
Completed |
Non-Squamous Non-Small Cell Lung Cancer |
NCT00773188 |
| Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT03887130 |
| To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma |
Recruiting |
NSCLC|EGFR |
NCT03656393 |
| Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) |
Unknown status |
Carcinoma, Invasive Ductal, Breast |
NCT01126138 |
| MEtronomic TrEatment Option in Advanced bReast cAncer |
Recruiting |
Breast Cancer |
NCT02954055 |
| Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma |
Completed |
Cervical Cancer Recurrent or Persistent|Palliative Treatment|Monoclonal Antibody in Cervical Cancer Treatment |
NCT02083211 |
| Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom |
Active, not recruiting |
Cervical Cancer |
NCT03413579 |
| Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients |
Unknown status |
Malignant Pleural Mesothelioma |
NCT01865045 |
| Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00054197 |
| Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease |
Completed |
Tumors|Hodgkins Disease|Non-Hodgkins Lymphoma |
NCT00364676 |
| Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab |
Terminated |
Breast Cancer |
NCT00130507 |
| Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00193362 |
| Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. |
Completed |
BRMS1|Performance Status Zero to Two for Beginning the Study|Patient With a Maximum of One Chemotherapy|Patient With Progression After Taxanes |
NCT01050322 |
| Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer |
Completed |
Breast Neoplasms |
NCT01325428 |
| Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors |
Not yet recruiting |
Pediatric Cancer |
NCT02897986 |
| Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00079287 |
| A Study of Atezolizumab Compared With Chemotherapy in Treatment NaĂŻve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy |
Recruiting |
Non-Small Cell Lung Cancer |
NCT03191786 |
| Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer |
Unknown status |
Head and Neck Neoplasms |
NCT01020864 |
| Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery |
Completed |
Lung Cancer |
NCT00057798 |
| A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT01196078 |
| A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer |
Recruiting |
HER2 Positive Breast Cancer |
NCT02362958 |
| Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00006215 |
| Efficacy Study of Outpatient Therapy for Lymphoma |
Completed |
Non-Hodgkin's Lymphoma|Hodgkin's Disease |
NCT00163761 |
| Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) |
Completed |
Non Small Cell Lung Carcinoma|Metastatic Breast Cancer |
NCT00890903 |
| Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer |
Completed |
Breast Neoplasm |
NCT00194740 |
| Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery |
Completed |
Lung Cancer |
NCT00309972 |
| Random Trial for Elderly Patients With NSCLC |
Unknown status |
Non-Small Cell Lung Cancer |
NCT00265694 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
Stage IIIb Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00042315 |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma |
Completed |
Lymphoma |
NCT00006029 |
| Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00242983 |
| Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) |
Completed |
NSCLC |
NCT00298415 |
| Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer |
Completed |
Cervical Cancer |
NCT00002813 |
| Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00253591 |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma |
Recruiting |
Diffuse Large B-cell Lymphoma |
NCT02733380 |
| Concomitant Radio-chemotherapy in the Elderly |
Completed |
Non Small Cell Lung Cancer |
NCT01029678 |
| Platinum Rechallenge in Patients With Platinum-sensitive mTNBC |
Recruiting |
Metastatic Breast Cancer |
NCT02607215 |
| Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE |
Completed |
Progress-free Survival|Overall Response Rate|Adverse Events |
NCT01291667 |
| Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients |
Unknown status |
Metastatic Breast Cancer |
NCT01802970 |
| A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. |
Recruiting |
Completely Resected NSCLC With Common EGFR Mutations |
NCT03381066 |
| Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer |
Completed |
Breast Neoplasms|Neoplasm Metastasis |
NCT00426530 |
| A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma |
Completed |
Hodgkin Disease |
NCT00636311 |
| S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003587 |
| Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia |
Completed |
Leukemia |
NCT00462787 |
| Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer |
Completed |
Carcinoma Breast Stage IV |
NCT00433095 |
| Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC. |
Unknown status |
Previously Treated Metastatic Non-Small Cell Lung Cancer |
NCT00238849 |
| Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer |
Completed |
Kidney Cancer |
NCT00003584 |
| Phase I Cetuximab and Concurrent Radio-chemotherapy |
Completed |
Non-small Cell Lung Cancer |
NCT00522886 |
| Combination Chemotherapy in Treating Patients With Advanced Cancer |
Completed |
Leukemia|Lymphoma|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00004105 |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer |
Available |
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation|Triple-Negative Breast Cancer |
NCT02985658 |
| SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
Completed |
Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma |
NCT00337194 |
| Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. |
Completed |
Hodgkin Lymphoma |
NCT01022996 |
| Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix |
Completed |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer |
NCT00064077 |
| LUX-Breast 2 |
N/A |
N/A |
NCT01271725 |
| Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy |
Completed |
Prostate Cancer |
NCT00627354 |
| Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage â…˘A NSCLC |
Completed |
Non Small Cell Lung Cancer |
NCT02497118 |
| Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer |
Active, not recruiting |
Breast Neoplasms|Malignant Tumor of the Breast |
NCT02229149 |
| Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00256815 |
| Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN) |
Completed |
Lung Cancer |
NCT01443078 |
| Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00842712 |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor |
Recruiting |
Desmoplastic Small Round Cell Tumor |
NCT04145349 |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00006372 |
| MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00401492 |
| PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma |
Active, not recruiting |
Pleural Mesothelioma Malignant Advanced |
NCT02991482 |
| Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine® |
Unknown status |
NSCLC |
NCT02354274 |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma |
Unknown status |
Hodgkin's Lymphoma |
NCT01884428 |
| Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00985855 |
| Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease |
Unknown status |
Non Small Cell Lung Cancer |
NCT01784549 |
| MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer |
Recruiting |
Breast Cancer Metastatic |
NCT03321981 |
| Chemoradiotherapy in Patients With Localised Lung Cancer |
Completed |
Non Small Cell Lung Carcinoma |
NCT00193921 |
| Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00004100 |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer |
Terminated |
Advanced Non-Small Cell Lung Cancer |
NCT00345059 |
| Chemotherapy and G-CSF for Mobilization |
Recruiting |
Multiple Myeloma |
NCT03442673 |
| Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer |
Completed |
Locally Advanced Non Small Cell Lung Cancer (NSCLC)* |
NCT01118676 |
| Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation |
Withdrawn |
NSCLC |
NCT02795884 |
| Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
Unknown status |
Prostate Cancer |
NCT00006114 |
| Study for Patients With Non Small Cell Lung Cancer (NSCLC) |
Unknown status |
Carcinoma, Non-Small-Cell Lung |
NCT00168883 |
| Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer |
Unknown status |
Locally Advanced Inoperable Non-small-lung Cancer |
NCT01203735 |
| Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients |
Unknown status |
Non-small-cell Lung Cancer |
NCT01843647 |
| The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy |
Unknown status |
Breast Cancer|Chemotherapy Effect|Disease-free Survival |
NCT03423849 |
| Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy |
Recruiting |
Primary Breast Cancer |
NCT03270007 |
| Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00434668 |
| Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas |
Completed |
Diffuse Large B-Cell Lymphoma |
NCT00842595 |
| Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors |
Recruiting |
Non-small Cell Lung Cancer Metastatic |
NCT03656094 |
| Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT |
Completed |
Hodgkin's Lymphoma |
NCT01478191 |
| Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy |
Recruiting |
Breast Cancer|Breast Neoplasms |
NCT03393741 |
| Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses |
Recruiting |
Diffuse Intrinsic Pontine Glioma |
NCT03620032 |
| Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer |
Unknown status |
Breast Neoplasms |
NCT02489409 |
| Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) |
Active, not recruiting |
Metastatic Triple Negative Breast Cancer |
NCT02555657 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00004093 |
| Trastuzumab & Pertuzumab Followed by T-DM1 in MBC |
Active, not recruiting |
Metastatic Breast Cancer |
NCT01835236 |
| Chemoradiotherapy of NSCLC Stage IIIB |
Completed |
NSCLC Stage IIIB|Concomitant Radiochemotherapy |
NCT00198432 |
| Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease |
Terminated |
Hodgkin Disease |
NCT00225173 |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. |
Active, not recruiting |
Breast Cancer Metastatic|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation |
NCT02000622 |
| Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT02720614 |
| Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) |
Recruiting |
Carcinoma, Non-Small-Cell Lung|Metastatic Lung Cancer|Non Small Cell Lung Cancer|Lung Adenocarcinoma Metastatic|Large Cell Lung Carcinoma Metastatic |
NCT03345810 |
| A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer (NSCLC) |
NCT01454934 |
| Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery |
Completed |
Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
NCT00194779 |
| To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer |
Unknown status |
Non-small Cell Lung Cancer Stage IIIA|Radiotherapy |
NCT02977169 |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma |
Recruiting |
Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma |
NCT02567435 |
| Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment |
Completed |
Lymphoma |
NCT00392691 |
| Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma |
Completed |
Non-Hodgkin's Lymphoma (CD20+) |
NCT00280878 |
| Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation |
Recruiting |
Non-small Cell Lung Cancer |
NCT02448797 |
| Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00863512 |
| Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal Cancer |
Unknown status |
Squamous Cell Esophageal Carcinoma |
NCT02188615 |
| Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy |
Completed |
Non-small Cell Lung Carcinoma |
NCT01648517 |
| The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00215930 |
| BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) |
Completed |
Lymphoma, Non-Hodgkin |
NCT00088530 |
| IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma |
Unknown status |
Hodgkin Lymphoma |
NCT01333605 |
| Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02) |
Suspended |
Metastatic Breast Cancer |
NCT03901339 |
| Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer |
Unknown status |
Breast Cancer |
NCT01950182 |
| Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) |
Terminated |
Advanced Cancer|Breast Cancer|Sarcoma|Pancreatic Cancer|Small Cell Lung Cancer|Ovarian |
NCT02331251 |
| Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT01687439 |
| The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial |
Unknown status |
Stage IV, NSCLC|Lung Neoplasms|Bronchial Neoplasms|Carcinoma, Bronchogenic|Lung Diseases|Neoplasms|Respiratory Tract Diseases|Respiratory Tract Neoplasms|Thoracic Neoplasms |
NCT03402048 |
| A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer |
Active, not recruiting |
Non - Small Cell Lung Cancer NSCLC |
NCT02352948 |
| ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer |
Active, not recruiting |
Breast Cancer |
NCT02574455 |
| G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients |
Completed |
Small Cell Lung Cancer |
NCT00401609 |
| Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas |
Active, not recruiting |
Aggressive Non-Hodgkin Lymphoma |
NCT03161054 |
| First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer |
Unknown status |
Chemotherapeutic Agent Toxicity|Fatigue|Lung Cancer|Musculoskeletal Complications |
NCT01097317 |
| A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). |
Recruiting |
Metastatic Breast Cancer |
NCT03355157 |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer |
Active, not recruiting |
HER-2 Positive Breast Cancer|Metastatic Neoplasm |
NCT02492711 |
| Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00198367 |
| A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer |
Completed |
Metastatic Breast Cancer |
NCT01310231 |
| Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy |
Terminated |
Non Small Cell Lung Carcinoma |
NCT00661011 |
| Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma |
Unknown status |
Malignant Mesothelioma |
NCT00354393 |
| Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00050973 |
| Chemotherapeutic Agents in Brain/Breast |
Completed |
Breast Cancer|Metastatic Cancer |
NCT00795678 |
| Curative Study of Chinese Traditional Medicine to Treat Lung Cancer |
Unknown status |
Cancer |
NCT02777788 |
| Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer, Non-Small Cell |
NCT00455572 |
| A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer |
Terminated |
Non Small Cell Lung Cancer |
NCT02117024 |
| Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer |
Unknown status |
Breast Cancer |
NCT01732939 |
| Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
Completed |
Prostate Cancer |
NCT00005847 |
| Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer |
Completed |
Lung Cancer|Non Small Cell Lung Carcinoma |
NCT00111839 |
| Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer |
Recruiting |
Breast Cancer |
NCT03839823 |
| Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer |
Completed |
Breast Cancer |
NCT00004237 |
| To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer |
Recruiting |
Non-small Cell Lung Cancer Stage IIIA|Radiotherapy |
NCT02974426 |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease |
Completed |
Hodgkin Disease|Hodgkin's Lymphoma|Lymphoma |
NCT00388349 |
| A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. |
Terminated |
Non-Squamous Non-Small Cell Lung Cancer |
NCT00642824 |
| Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT00499109 |
| Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer |
Not yet recruiting |
Susceptibility, Genetic|Chemotherapy Effect |
NCT03359694 |
| A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer |
Active, not recruiting |
HER2-positive Locally Advanced or Metastatic Breast Cancer |
NCT02514681 |
| Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs |
Recruiting |
Primary Mediastinal Large B-cell Lymphoma |
NCT03346642 |
| A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer |
Withdrawn |
Neoplasms, Breast |
NCT01137994 |
| First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer |
Terminated |
Non Small Cell Lung Cancer |
NCT01038037 |
| Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation |
Active, not recruiting |
Non-small Cell Lung Cancer Stage III |
NCT01683175 |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients |
Terminated |
Breast Cancer|HER2 Positive Breast Cancer |
NCT02213744 |
| Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer |
Terminated |
Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
NCT00194792 |
| Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] |
Active, not recruiting |
Non-Small Cell Lung Cancer |
NCT02486718 |
| SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations |
Unknown status |
NSCLC|SBRT|GM-CSF |
NCT02940990 |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) |
Active, not recruiting |
Breast Neoplasms|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation |
NCT01945775 |
| The BEACON Study (Breast Cancer Outcomes With NKTR-102) |
Completed |
Locally Recurrent Breast Cancer|Metastatic Breast Cancer |
NCT01492101 |
| A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer |
Recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT03456076 |
| A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain |
Terminated |
Breast Cancer |
NCT00476827 |
| First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
Unknown status |
Lung Cancer |
NCT00736814 |
| Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery |
Completed |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer |
NCT00005838 |
| Phase II Iressa + Irradiation Followed by Chemo in NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT00333294 |
| Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00312819 |
| Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients |
Unknown status |
Malignant Hydrothorax|Non Small Cell Lung Cancer |
NCT02579564 |
| Trial of ZW25 in Patients With Advanced HER2-expressing Cancers |
Recruiting |
HER2-expressing Cancers |
NCT02892123 |
| Chemotherapy in Treating Patients With Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT01067794 |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer |
Terminated |
Non-Small-Cell Lung Cancer |
NCT00705549 |
| Clinical Study of Chemotherapy Combined With Chinese Medicine on Survival Affect of Elderly Patients With Lung Cancer |
Completed |
Cancer |
NCT01780181 |
| Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer |
Active, not recruiting |
Lung Cancer |
NCT02644252 |
| PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer |
Recruiting |
Breast Cancer Model|Effects of Chemotherapy|Breast Cancer |
NCT03006614 |
| Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients |
Terminated |
NSCLC |
NCT00754364 |
| Basket Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors |
Recruiting |
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers |
NCT03386721 |
| "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" |
Unknown status |
Infiltrating Duct and Lobular Carcinoma In Situ|Invasive Lobular Breast Carcinoma|Inflammatory Breast Carcinoma |
NCT01641406 |
| Loreline Study: Characterization of Long Responders Under Eribuline |
Recruiting |
Breast Cancer Patients|Therapy Related Tumor |
NCT03771183 |
| Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas |
Unknown status |
Esophageal Squamous Cell Carcinoma |
NCT02665702 |
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine |
Active, not recruiting |
Metastasis|Breast Cancer |
NCT02915744 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery |
Active, not recruiting |
Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7 |
NCT00324805 |
| Maine |
Waterville |
United States|York Hospital |
Scarborough |
| Pennsylvania |
Erie |
United States|UPMC Hamot |
Ephrata |
| A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation |
Not yet recruiting |
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation |
NCT04296370 |
| Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00391586 |
| Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM" |
Completed |
Invasive Breast Cancer |
NCT02244580 |
| Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients |
Unknown status |
Metastatic Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
NCT02175446 |
| Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma |
Unknown status |
Malignant Mesothelioma |
NCT00030459 |
| Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00005825 |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC |
Recruiting |
Breast Cancer Metastatic |
NCT04262804 |
| Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma |
Unknown status |
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma |
NCT01026220 |
| Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy |
Completed |
Lung Cancer|Non Small Cell Lung Carcinoma|Hypermethylation |
NCT01209520 |
| A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer |
Terminated |
Breast Cancer |
NCT00235235 |
| Managing Medication-induced Constipation in Cancer: A Clinical Trial |
Completed |
Constipation |
NCT01416909 |
| Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00686959 |
| contact 1-877-CTLILLY (1-877-285-4559 |
EST) |
Taichung |
Taiwan|For additional information regarding investigative sites for this trial |
| A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients |
Completed |
Cancer |
NCT00659269 |
| Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer |
Completed |
Recurrent or Metastatic Head and Neck Carcinoma |
NCT02347332 |
| Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT01494558 |
| Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) |
Recruiting |
Organoids|HNSCC|Epithelial Ovarian Cancer|Colorectal Cancer |
NCT04279509 |
| Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer (NSCLC) |
NCT00770588 |
| Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC |
Active, not recruiting |
Non-small Cell Lung Cancer |
NCT02367443 |
| Sorafenib in Resected Non-small Cell Lung Carcinoma |
Terminated |
Carcinoma, Non-Small-Cell Lung |
NCT00532025 |
| An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) |
Recruiting |
Squamous-Cell Lung Cancer |
NCT03823625 |
| Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer |
Unknown status |
Non Small Cell Lung Cancer |
NCT01171170 |
| Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer |
Recruiting |
Metastatic Breast Cancer |
NCT02448420 |
| Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy |
Terminated |
Carcinoma, Non-small-cell Lung |
NCT02004184 |
| CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) |
Withdrawn |
Non-small Cell Lung Cancer |
NCT01533727 |
| Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC |
Unknown status |
Carcinoma, Non-Small-Cell Lung |
NCT00561054 |
| Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer |
Recruiting |
Non Small Cell Lung Cancer |
NCT02679963 |
| A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) |
Completed |
Metastatic Breast Cancer |
NCT00281697 |
| 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC) |
Terminated |
Non Small Cell Lung Cancer |
NCT01124812 |
| Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT) |
Suspended |
NSCLC Stage IIIA/B |
NCT02118415 |
| Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen |
Unknown status |
Cancer|Lung Cancer |
NCT01850147 |
| the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs |
Completed |
Non-small Cell Lung Cancer(NSCLC) |
NCT02603003 |
| Detect V / CHEVENDO (Chemo vs. Endo) |
Recruiting |
Metastatic Breast Cancer |
NCT02344472 |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma |
Recruiting |
Hodgkin Lymphoma|Relapsed or Refractory Hodgkin Lymphoma |
NCT03618550 |
| DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs |
Unknown status |
HER2-negative Metastatic Breast Cancer|HER2-positive Circulating Tumor Cells |
NCT01619111 |
| Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy |
Terminated |
Non Small Cell Lung Cancer|Locally Advanced Disease |
NCT01664663 |
| Efficacy Study of Integrated TCM Combined With Chemotherapy in Postoperative NSCLC Patients |
Completed |
Non-small Cell Lung Cancer |
NCT01441752 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer |
Completed |
Prostate Cancer |
NCT00003400 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer |
Active, not recruiting |
Metastatic Breast Cancer |
NCT02299999 |
| Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies |
Completed |
Leukemia|Multiple Myeloma |
NCT00477035 |
| Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer |
Recruiting |
Colorectal Cancer Metastatic |
NCT03251612 |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) |
Recruiting |
Small Cell Carcinoma|Carcinoma, Non-Small-Cell Lung|Neuroendocrine Tumors|Ovarian Epithelial Cancer |
NCT02489903 |
| A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma. |
Completed |
Sarcoma |
NCT00643565 |
| NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed |
Completed |
Malignant Pleural Mesothelioma |
NCT01098266 |
| Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients |
Completed |
Breast Cancer |
NCT03541863 |
| Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer |
Unknown status |
Non-small Cell Lung Cancer|Locally Advanced Disease |
NCT01167530 |
| Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00002823 |
| A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer |
Completed |
Breast Cancer |
NCT01156753 |
| Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue |
Terminated |
Metastatic Breast Cancer|Fatigue |
NCT02645175 |
| Breast Cancer Treatment Based on Organ-like Culture |
Enrolling by invitation |
Breast Cancer Organoids |
NCT03925233 |
| Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy |
Unknown status |
Non-Small Cell Lung Cancer |
NCT00300729 |
| Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients |
Active, not recruiting |
Metastatic Breast Cancer |
NCT02829008 |
| Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma |
Completed |
Malignant Mesothelioma |
NCT00075699 |
| Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Withdrawn |
Lung Cancer |
NCT00055887 |
| Study of Cemiplimab in Adults With Cervical Cancer |
Recruiting |
Squamous Cell Carcinoma (SCC)|Recurrent or Metastatic, Platinum-refractory Cervical Cancer |
NCT03257267 |
| Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma |
Completed |
Childhood Favorable Prognosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma |
NCT00302003 |
| Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer |
Unknown status |
Squamous Cell Esophageal Carcinoma |
NCT01216527 |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease |
Not yet recruiting |
Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA |
NCT03770299 |
| CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility |
Recruiting |
Lung Neoplasms|Lung Cancer|Neoplasm of Lung|Non Small Cell Lung Cancer |
NCT03986463 |
| Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer |
Completed |
Breast Neoplasms |
NCT00246571 |
| Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) |
Unknown status |
Peripheral T-Cell Lymphoma |
NCT00632827 |
| Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00002887 |
| Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00083083 |
| A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Non Small Cell Lung Cancer |
NCT02998528 |
| Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
Completed |
Adenocarcinoma of Colon|Adenocarcinoma of Rectum|Metastatic Disease |
NCT01703910 |
| Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00148395 |
| Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma |
Terminated |
Lymphoma |
NCT00920153 |
| Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer |
Unknown status |
Lung Cancer |
NCT00003240 |
| Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma |
Active, not recruiting |
Lymphoma |
NCT00574496 |
| Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00003159 |
| Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma |
Unknown status |
Sarcoma |
NCT00379457 |
| Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer (NSCLC) |
NCT00820755 |
| Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer |
Terminated |
Breast Cancer |
NCT01698281 |
| A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) |
Completed |
Non-Small Cell Lung Cancer|Brain Neoplasms |
NCT00312728 |
| SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer |
Recruiting |
Metastatic Breast Cancer |
NCT03262935 |
| Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma |
Unknown status |
Carcinoma, Non-Small-Cell Lung|Synchronous Neoplasms |
NCT02805530 |
| Study of Neoadjuvant Chemotherapy of Breast Cancer |
Unknown status |
Breast Cancer |
NCT00830544 |
| CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy |
Not yet recruiting |
Nasopharyngeal Carcinoma |
NCT03529279 |
| Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study |
Recruiting |
Glioblastoma|Brain Metastases |
NCT03951142 |
| PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study |
Not yet recruiting |
Carcinoma, Non-Small-Cell Lung|Immune-Related Adverse Events |
NCT04115410 |
| A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA) |
Completed |
Breast Cancer |
NCT01250379 |
